Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b open-label E/C/F/TAF in HIV-1 and hepatitis B co-infected adults
jRCT2080222540Phase 3
- Sponsor
- Japan Tobacco
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) and Chronic Hepatitis B (CHB), sponsored by Japan Tobacco.
02
Drugs
elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2080222540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222540.